Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 11, 2025, reports the completion of a major strategic divestiture by Coherus BioSciences, Inc. (the "Company"). The filing details the closing of the sale of the UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd. This transaction marks a significant shift in the Company's business model, with the entire biosimilar business (including UDENYCA, YUSIMRY, and CIMERLI) to be presented as discontinued operations.
Key Financial Metrics and Transaction Details
- Transaction Consideration: The Company received upfront, all-cash consideration of $483.4 million for the UDENYCA franchise.
- Inventory Component: The upfront payment includes $118.4 million specifically allocated for UDENYCA product inventory.
- Contingent Payments: The Company is eligible for two additional milestone payments of $37.5 million each, contingent on Net Sales thresholds of $300 million and $350 million over specific four-quarter periods ending in 2026 and 2027, respectively.
- Debt Repurchase: The Company expects to repurchase all outstanding 1.500% Convertible Senior Subordinated Notes due 2026 on April 15, 2025. Pro forma assumptions include a repurchase of $230 million in aggregate principal amount, plus accrued interest and transaction expenses.
- Revenue Participation Right: Pro forma financials assume a payment of $49.1 million related to the UDENYCA portion of a prior agreement with Coduet Royalty Holdings, LLC.
- Employee Transfer: Approximately 40 full-time employees transferred to Intas on April 14, 2025.
Material Changes Versus Prior Period
The primary material change is the divestiture of the UDENYCA franchise, which was previously a core operating asset. Consequently, the Company's financial reporting will shift to present the entire biosimilar business as discontinued operations. The filing includes unaudited pro forma condensed combined financial information that recasts the year ended December 31, 2023, to exclude results from discontinued operations and presents only income (loss) from continuing operations. The pro forma balance sheet as of December 31, 2024, is prepared as though the UDENYCA disposition occurred on that date.
Guidance, Outlook, and Risks
Strategic Shift: The UDENYCA Disposition represents a strategic shift away from the biosimilar business. The Company is moving toward a portfolio focused on continuing operations, excluding the UDENYCA, YUSIMRY, and CIMERLI franchises.
Outlook: Future cash flows from the transaction depend on the achievement of Net Sales milestones by Intas for the UDENYCA product. The Company also anticipates the completion of the Convertible Notes repurchase shortly after the filing date.
Risks and Contingencies: The upfront consideration is subject to certain adjustments to be finalized post-closing. The contingent payments are not guaranteed and depend on future sales performance of the divested asset.
Key Facts for Investor Verification
- Verify the final adjusted consideration amount for the UDENYCA Disposition once post-closing adjustments are finalized.
- Confirm the execution and terms of the Convertible Notes repurchase on April 15, 2025.
- Review the unaudited pro forma financial statements (Exhibit 99.2) to understand the Company's financial position excluding discontinued operations.
- Monitor future press releases regarding the achievement of the $300 million and $350 million Net Sales milestones for potential contingent payments.
- Assess the impact of the 40-employee transfer on the Company's remaining operational capacity and cost structure.